Trial Outcomes & Findings for Study of the Gut Hormone Analogue G3215 in Adult Subjects (NCT NCT02692040)
NCT ID: NCT02692040
Last Updated: 2020-12-23
Results Overview
As assessed by reporting of adverse events, vital signs, physical examination, clinical laboratory safety assessments, and ECG parameters. Possibly or definitely related to study drug
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
90 participants
Primary outcome timeframe
up to 28 days after dosing
Results posted on
2020-12-23
Participant Flow
Recruited by Covance Clinical Research Unit, Leeds, UK
Participant milestones
| Measure |
Placebo (A) - Saline
0.9% saline single subcutaneous injection
Placebo: 0.9% saline
|
G3215 Single Ascending Dose (A1)
Sequential cross-over group received either Saline or 0.1 mg dose G3215 (A1) single dose, subcutaneous injection in the first treatment period; Saline or 0.5 mg dose G3215 single dose, subcutaneous injection in the second period, Saline or 1.5 mg dose G3215 single dose, subcutaneous injection in the third treatment period. Treatment periods were 12-15 days apart.
|
4 mg Dose G3215 (A2) With Varied Formulation
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A3) With Varied Formulation
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A4) With Varied Formulation
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A5) With Varied Formulation
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
8 mg Dose G3215 (A7)
8 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
10 mg Dose G3215 (A6)
10 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
12 mg Dose G3215 (A8)
12 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
16 mg Dose G3215 (A9)
16 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
32 mg Dose G3215 (A10)
32 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
48 mg Dose G3215 (A11)
48 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
Placebo (B) - Saline
0.9% saline multiple subcutaneous injection:
5 injections over a 4 week treatment period
Placebo: 0.9% saline
|
12-24 mg (B1) Dose of G3215
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses to a max of 24 mg.
G3215: Gut hormone analogue
|
6-10 mg (B2) Dose of G3215
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses to a max of 10 mg.
G3215: Gut hormone analogue
|
5-16 mg (B3) Dose of G3215
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses to a max of 16 mg.
G3215: Gut hormone analogue
|
3.2mg (C) Infusion Pump Dose of G3215
G3215 subcutaneous infusion over a 4 day treatment period at escalating doses to a max of 3.2 mg (with either the first or last day administering infusion of placebo \[saline\]).
G3215: Gut hormone analogue
Placebo: 0.9% saline
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
10
|
4
|
5
|
5
|
4
|
5
|
5
|
5
|
5
|
4
|
5
|
5
|
6
|
6
|
6
|
6
|
4
|
|
Overall Study
COMPLETED
|
10
|
4
|
5
|
5
|
4
|
5
|
5
|
5
|
5
|
4
|
5
|
5
|
5
|
3
|
5
|
5
|
4
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
1
|
1
|
0
|
Reasons for withdrawal
| Measure |
Placebo (A) - Saline
0.9% saline single subcutaneous injection
Placebo: 0.9% saline
|
G3215 Single Ascending Dose (A1)
Sequential cross-over group received either Saline or 0.1 mg dose G3215 (A1) single dose, subcutaneous injection in the first treatment period; Saline or 0.5 mg dose G3215 single dose, subcutaneous injection in the second period, Saline or 1.5 mg dose G3215 single dose, subcutaneous injection in the third treatment period. Treatment periods were 12-15 days apart.
|
4 mg Dose G3215 (A2) With Varied Formulation
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A3) With Varied Formulation
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A4) With Varied Formulation
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A5) With Varied Formulation
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
8 mg Dose G3215 (A7)
8 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
10 mg Dose G3215 (A6)
10 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
12 mg Dose G3215 (A8)
12 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
16 mg Dose G3215 (A9)
16 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
32 mg Dose G3215 (A10)
32 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
48 mg Dose G3215 (A11)
48 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
Placebo (B) - Saline
0.9% saline multiple subcutaneous injection:
5 injections over a 4 week treatment period
Placebo: 0.9% saline
|
12-24 mg (B1) Dose of G3215
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses to a max of 24 mg.
G3215: Gut hormone analogue
|
6-10 mg (B2) Dose of G3215
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses to a max of 10 mg.
G3215: Gut hormone analogue
|
5-16 mg (B3) Dose of G3215
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses to a max of 16 mg.
G3215: Gut hormone analogue
|
3.2mg (C) Infusion Pump Dose of G3215
G3215 subcutaneous infusion over a 4 day treatment period at escalating doses to a max of 3.2 mg (with either the first or last day administering infusion of placebo \[saline\]).
G3215: Gut hormone analogue
Placebo: 0.9% saline
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Protocol Violation
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
Overall Study
Adverse Event
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
1
|
1
|
0
|
Baseline Characteristics
Study of the Gut Hormone Analogue G3215 in Adult Subjects
Baseline characteristics by cohort
| Measure |
Placebo (A2-A11) - Saline
n=10 Participants
Single subcutaneous injection of 0.9% saline
|
G3215 Single Ascending Dose (A1)
n=4 Participants
Sequential cross-over group received either Saline or 0.1 mg dose G3215 (A1) single dose, subcutaneous injection in the first treatment period; Saline or 0.5 mg dose G3215 single dose, subcutaneous injection in the second period, Saline or 1.5 mg dose G3215 single dose, subcutaneous injection in the third treatment period. Treatment periods were 12-15 days apart.
|
4 mg Dose G3215 (A2)
n=5 Participants
4 mg G3215 single dose, subcutaneous injection
|
4 mg Dose G3215 (A3)
n=5 Participants
4 mg G3215 single dose, subcutaneous injection
|
4 mg Dose G3215 (A4)
n=4 Participants
4 mg G3215 single dose, subcutaneous injection
|
4 mg Dose G3215 (A5)
n=5 Participants
4 mg G3215 single dose, subcutaneous injection
|
8 mg Dose G3215 (A7)
n=5 Participants
8 mg G3215 single dose, subcutaneous injection
|
10 mg Dose G3215 (A6)
n=5 Participants
10 mg G3215 single dose, subcutaneous injection
|
12 mg Dose G3215 (A8)
n=5 Participants
12 mg G3215 single dose, subcutaneous injection
|
16 mg Dose G3215 (A9)
n=4 Participants
16 mg G3215 single dose, subcutaneous injection
|
32 mg Dose G3215 (A10)
n=5 Participants
32 mg G3215 single dose, subcutaneous injection
|
48 mg Dose G3215 (A11)
n=5 Participants
48 mg G3215 single dose, subcutaneous injection
|
Placebo (B) - Saline
n=6 Participants
0.9% saline multiple subcutaneous injection
5 injections over a 4 week treatment period
Placebo: 0.9% saline
|
12-24 mg (B1) Dose of G3215
n=6 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses to a max of 24 mg.
G3215: Gut hormone analogue
|
6-10 mg (B2) Dose of G3215
n=6 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses to a max of 10 mg.
G3215: Gut hormone analogue
|
5-16 mg (B3) Dose of G3215
n=6 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses to a max of 16 mg.
G3215: Gut hormone analogue
|
3.2mg (C) Infusion Pump Dose of G3215
n=4 Participants
G3215 subcutaneous infusion over a 4 day treatment period at escalating doses to a max of 3.2 mg (with either the first or last day administering infusion of placebo \[saline\]).
G3215: Gut hormone analogue
Placebo: 0.9% saline
|
Total
n=90 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Region of Enrollment
United Kingdom
|
10 participants
n=5 Participants
|
4 participants
n=7 Participants
|
5 participants
n=5 Participants
|
5 participants
n=4 Participants
|
4 participants
n=21 Participants
|
5 participants
n=8 Participants
|
5 participants
n=8 Participants
|
5 participants
n=24 Participants
|
5 participants
n=42 Participants
|
4 participants
n=42 Participants
|
5 participants
n=42 Participants
|
5 participants
n=42 Participants
|
6 participants
n=36 Participants
|
6 participants
n=36 Participants
|
6 participants
n=24 Participants
|
6 participants
n=135 Participants
|
4 participants
n=136 Participants
|
98 participants
n=44 Participants
|
|
Body Weight (kg)
|
88.9 kg
STANDARD_DEVIATION 10.20 • n=5 Participants
|
89.2 kg
STANDARD_DEVIATION 7.75 • n=7 Participants
|
83.7 kg
STANDARD_DEVIATION 7.98 • n=5 Participants
|
99.6 kg
STANDARD_DEVIATION 10.72 • n=4 Participants
|
94.6 kg
STANDARD_DEVIATION 7.00 • n=21 Participants
|
92.2 kg
STANDARD_DEVIATION 9.34 • n=8 Participants
|
92.3 kg
STANDARD_DEVIATION 8.46 • n=8 Participants
|
92.1 kg
STANDARD_DEVIATION 9.48 • n=24 Participants
|
92.4 kg
STANDARD_DEVIATION 8.32 • n=42 Participants
|
96.3 kg
STANDARD_DEVIATION 16.36 • n=42 Participants
|
89.3 kg
STANDARD_DEVIATION 5.16 • n=42 Participants
|
85.9 kg
STANDARD_DEVIATION 14.88 • n=42 Participants
|
88.3 kg
STANDARD_DEVIATION 10.42 • n=36 Participants
|
90.2 kg
STANDARD_DEVIATION 3.08 • n=36 Participants
|
92.1 kg
STANDARD_DEVIATION 13.72 • n=24 Participants
|
93.6 kg
STANDARD_DEVIATION 13.51 • n=135 Participants
|
87.9 kg
STANDARD_DEVIATION 5.68 • n=136 Participants
|
90.9 kg
STANDARD_DEVIATION 9.9 • n=44 Participants
|
|
BMI (kg/m^2)
|
28.5 kg/m^2
STANDARD_DEVIATION 2.51 • n=5 Participants
|
29.1 kg/m^2
STANDARD_DEVIATION 1.80 • n=7 Participants
|
27.4 kg/m^2
STANDARD_DEVIATION 1.94 • n=5 Participants
|
29.8 kg/m^2
STANDARD_DEVIATION 2.97 • n=4 Participants
|
28.5 kg/m^2
STANDARD_DEVIATION 2.46 • n=21 Participants
|
29.5 kg/m^2
STANDARD_DEVIATION 2.24 • n=8 Participants
|
30.0 kg/m^2
STANDARD_DEVIATION 2.98 • n=8 Participants
|
29.3 kg/m^2
STANDARD_DEVIATION 3.45 • n=24 Participants
|
28.2 kg/m^2
STANDARD_DEVIATION 2.50 • n=42 Participants
|
29.7 kg/m^2
STANDARD_DEVIATION 4.31 • n=42 Participants
|
28.8 kg/m^2
STANDARD_DEVIATION 1.78 • n=42 Participants
|
28.0 kg/m^2
STANDARD_DEVIATION 3.38 • n=42 Participants
|
28.6 kg/m^2
STANDARD_DEVIATION 3.72 • n=36 Participants
|
29.0 kg/m^2
STANDARD_DEVIATION 1.76 • n=36 Participants
|
29.4 kg/m^2
STANDARD_DEVIATION 3.94 • n=24 Participants
|
29.5 kg/m^2
STANDARD_DEVIATION 3.40 • n=135 Participants
|
29.0 kg/m^2
STANDARD_DEVIATION 1.48 • n=136 Participants
|
28.9 kg/m^2
STANDARD_DEVIATION 2.7 • n=44 Participants
|
|
Age, Continuous
|
40.1 years
STANDARD_DEVIATION 16.2 • n=5 Participants
|
47 years
STANDARD_DEVIATION 14.0 • n=7 Participants
|
39 years
STANDARD_DEVIATION 7.3 • n=5 Participants
|
40 years
STANDARD_DEVIATION 8.8 • n=4 Participants
|
38 years
STANDARD_DEVIATION 10.1 • n=21 Participants
|
47 years
STANDARD_DEVIATION 14.3 • n=8 Participants
|
30 years
STANDARD_DEVIATION 15.2 • n=8 Participants
|
48 years
STANDARD_DEVIATION 7.9 • n=24 Participants
|
33 years
STANDARD_DEVIATION 12.8 • n=42 Participants
|
45 years
STANDARD_DEVIATION 9.0 • n=42 Participants
|
39 years
STANDARD_DEVIATION 11.7 • n=42 Participants
|
49 years
STANDARD_DEVIATION 10.9 • n=42 Participants
|
47 years
STANDARD_DEVIATION 8.7 • n=36 Participants
|
45 years
STANDARD_DEVIATION 4.3 • n=36 Participants
|
47 years
STANDARD_DEVIATION 13.7 • n=24 Participants
|
45 years
STANDARD_DEVIATION 14.0 • n=135 Participants
|
48 years
STANDARD_DEVIATION 16.3 • n=136 Participants
|
42.7 years
STANDARD_DEVIATION 12.2 • n=44 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
5 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
5 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
6 Participants
n=36 Participants
|
6 Participants
n=36 Participants
|
6 Participants
n=24 Participants
|
6 Participants
n=135 Participants
|
4 Participants
n=136 Participants
|
90 Participants
n=44 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
10 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
5 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
5 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
6 Participants
n=36 Participants
|
6 Participants
n=36 Participants
|
6 Participants
n=24 Participants
|
6 Participants
n=135 Participants
|
4 Participants
n=136 Participants
|
90 Participants
n=44 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=135 Participants
|
0 Participants
n=136 Participants
|
0 Participants
n=44 Participants
|
PRIMARY outcome
Timeframe: up to 28 days after dosingAs assessed by reporting of adverse events, vital signs, physical examination, clinical laboratory safety assessments, and ECG parameters. Possibly or definitely related to study drug
Outcome measures
| Measure |
Placebo (A) - Saline
n=13 Participants
0.9% saline single subcutaneous injection
Placebo: 0.9% saline
|
0.1 mg Dose G3215 (A1)
n=3 Participants
0.1 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
0.5 mg Dose G3215 (A1)
n=3 Participants
0.5 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
1.5 mg Dose G3215 (A1)
n=3 Participants
1.5 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A2)
n=5 Participants
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A3)
n=5 Participants
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A4)
n=4 Participants
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A5)
n=5 Participants
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
8 mg Dose G3215 (A7)
n=5 Participants
8 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
10 mg Dose G3215 (A6)
n=5 Participants
10 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
12 mg Dose G3215 (A8)
n=5 Participants
12 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
16 mg Dose G3215 (A9)
n=4 Participants
16 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
32 mg Dose G3215 (A10)
n=5 Participants
32 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
48 mg Dose G3215 (A11)
n=5 Participants
48 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
Placebo (B) - Saline
n=6 Participants
0.9% saline multiple subcutaneous injection: 5 injections over a 4 week treatment period
Placebo: 0.9% saline
|
5mg G3215 (B)
n=6 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses
G3215: Gut hormone analogue
|
6 mg G3215 (B)
n=6 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses
G3215: Gut hormone analogue
|
7 mg G3215 (B)
n=6 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
8 mg G3215 (B)
n=6 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
10 mg G3215 (B)
n=8 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
12 mg G3215 (B)
n=1 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
16 mg G3215 (B)
n=7 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
20 mg G3215 (B)
n=3 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
24 mg G3215 (B)
n=6 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
Placebo (C)
n=4 Participants
Placebo: 0.9% saline
|
0.6 mg/24h (C) Infusion Pump Dose of G3215
n=1 Participants
G3215 subcutaneous infusion of 0.6 mg over 24h treatment period.
G3215: Gut hormone analogue
|
0.7 mg/24h (C) Infusion Pump Dose of G3215
n=2 Participants
G3215 subcutaneous infusion of 0.7 mg over 24h treatment period.
G3215: Gut hormone analogue
|
0.8 mg/24h (C) Infusion Pump Dose of G3215
n=1 Participants
G3215 subcutaneous infusion of 0.8 mg over 24h treatment period.
G3215: Gut hormone analogue
|
1 mg/24h (C) Infusion Pump Dose of G3215
n=1 Participants
G3215 subcutaneous infusion of 1 mg over 24h treatment period.
G3215: Gut hormone analogue
|
1.1 mg/24h (C) Infusion Pump Dose of G3215
n=1 Participants
G3215 subcutaneous infusion of 1.1 mg over 24h treatment period.
G3215: Gut hormone analogue
|
1.4 mg/24h (C) Infusion Pump Dose of G3215
n=1 Participants
G3215 subcutaneous infusion of 1.4 mg over 24h treatment period.
G3215: Gut hormone analogue
|
1.5 mg/24h (C) Infusion Pump Dose of G3215
n=3 Participants
G3215 subcutaneous infusion of 1.5 mg over 24h treatment period.
G3215: Gut hormone analogue
|
1.8 mg/24h (C) Infusion Pump Dose of G3215
n=1 Participants
G3215 subcutaneous infusion of 1.8 mg over 24h treatment period.
G3215: Gut hormone analogue
|
2.2 mg/24h (C) Infusion Pump Dose of G3215
n=1 Participants
G3215 subcutaneous infusion of 2.2 mg over 24h treatment period.
G3215: Gut hormone analogue
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]
|
2 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
4 Participants
|
4 Participants
|
2 Participants
|
4 Participants
|
4 Participants
|
5 Participants
|
5 Participants
|
4 Participants
|
5 Participants
|
5 Participants
|
2 Participants
|
5 Participants
|
6 Participants
|
5 Participants
|
6 Participants
|
7 Participants
|
0 Participants
|
4 Participants
|
3 Participants
|
6 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: up to day 4 (am) for Part A, day 31 (pm) for Part B and day 5 (am) for Part CPopulation: Completers
Summary of Time-Matched % Change from Baseline in Body Weight (AM Baseline = Day 1 AM; PM Baseline = Day -1 PM
Outcome measures
| Measure |
Placebo (A) - Saline
n=13 Participants
0.9% saline single subcutaneous injection
Placebo: 0.9% saline
|
0.1 mg Dose G3215 (A1)
n=3 Participants
0.1 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
0.5 mg Dose G3215 (A1)
n=3 Participants
0.5 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
1.5 mg Dose G3215 (A1)
n=3 Participants
1.5 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A2)
n=5 Participants
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A3)
n=5 Participants
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A4)
n=4 Participants
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A5)
n=5 Participants
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
8 mg Dose G3215 (A7)
n=5 Participants
8 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
10 mg Dose G3215 (A6)
n=5 Participants
10 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
12 mg Dose G3215 (A8)
n=5 Participants
12 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
16 mg Dose G3215 (A9)
n=4 Participants
16 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
32 mg Dose G3215 (A10)
n=5 Participants
32 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
48 mg Dose G3215 (A11)
n=5 Participants
48 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
Placebo (B) - Saline
n=5 Participants
0.9% saline multiple subcutaneous injection: 5 injections over a 4 week treatment period
Placebo: 0.9% saline
|
5mg G3215 (B)
n=3 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses
G3215: Gut hormone analogue
|
6 mg G3215 (B)
n=5 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses
G3215: Gut hormone analogue
|
7 mg G3215 (B)
n=4 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
8 mg G3215 (B)
n=2 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
10 mg G3215 (B)
n=2 Participants
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
12 mg G3215 (B)
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
16 mg G3215 (B)
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
20 mg G3215 (B)
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
24 mg G3215 (B)
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
Placebo (C)
Placebo: 0.9% saline
|
0.6 mg/24h (C) Infusion Pump Dose of G3215
G3215 subcutaneous infusion of 0.6 mg over 24h treatment period.
G3215: Gut hormone analogue
|
0.7 mg/24h (C) Infusion Pump Dose of G3215
G3215 subcutaneous infusion of 0.7 mg over 24h treatment period.
G3215: Gut hormone analogue
|
0.8 mg/24h (C) Infusion Pump Dose of G3215
G3215 subcutaneous infusion of 0.8 mg over 24h treatment period.
G3215: Gut hormone analogue
|
1 mg/24h (C) Infusion Pump Dose of G3215
G3215 subcutaneous infusion of 1 mg over 24h treatment period.
G3215: Gut hormone analogue
|
1.1 mg/24h (C) Infusion Pump Dose of G3215
G3215 subcutaneous infusion of 1.1 mg over 24h treatment period.
G3215: Gut hormone analogue
|
1.4 mg/24h (C) Infusion Pump Dose of G3215
G3215 subcutaneous infusion of 1.4 mg over 24h treatment period.
G3215: Gut hormone analogue
|
1.5 mg/24h (C) Infusion Pump Dose of G3215
G3215 subcutaneous infusion of 1.5 mg over 24h treatment period.
G3215: Gut hormone analogue
|
1.8 mg/24h (C) Infusion Pump Dose of G3215
G3215 subcutaneous infusion of 1.8 mg over 24h treatment period.
G3215: Gut hormone analogue
|
2.2 mg/24h (C) Infusion Pump Dose of G3215
G3215 subcutaneous infusion of 2.2 mg over 24h treatment period.
G3215: Gut hormone analogue
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Body Weight (Percentage Change From Baseline)
|
0.1 Percentage change
Standard Deviation 0.97
|
0.2 Percentage change
Standard Deviation 0.47
|
0.8 Percentage change
Standard Deviation 0.15
|
0.1 Percentage change
Standard Deviation 0.42
|
0.9 Percentage change
Standard Deviation 0.68
|
0.2 Percentage change
Standard Deviation 0.49
|
-0.7 Percentage change
Standard Deviation 0.29
|
0.4 Percentage change
Standard Deviation 0.7
|
-0.7 Percentage change
Standard Deviation 0.73
|
-1.4 Percentage change
Standard Deviation 0.44
|
-0.1 Percentage change
Standard Deviation 0.53
|
-0.1 Percentage change
Standard Deviation 0.51
|
-1.7 Percentage change
Standard Deviation 1.16
|
-0.9 Percentage change
Standard Deviation 0.74
|
-1.4 Percentage change
Standard Deviation 1.26
|
-3.7 Percentage change
Standard Deviation 2.58
|
-5.3 Percentage change
Standard Deviation 3.79
|
-4.5 Percentage change
Standard Deviation 1.72
|
-3.2 Percentage change
Standard Deviation 0
|
-3.0 Percentage change
Standard Deviation 0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
Placebo (A) - Saline
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
0.1 mg Dose G3215 (A1)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
0.5 mg Dose G3215 (A1)
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
1.5 mg Dose G3215 (A1)
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
4 mg Dose G3215 (A2)
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
4 mg Dose G3215 (A3)
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
4 mg Dose G3215 (A4)
Serious events: 1 serious events
Other events: 4 other events
Deaths: 1 deaths
4 mg Dose G3215 (A5)
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
8 mg Dose G3215 (A7)
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
10 mg Dose G3215 (A6)
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
12 mg Dose G3215 (A8)
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
16 mg Dose G3215 (A9)
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
32 mg Dose G3215 (A10)
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
48 mg Dose G3215 (A11)
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
Placebo (B) - Saline
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
5 mg G3215 (B)
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
6 mg G3215 (B)
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
7 mg G3215 (B)
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
8 mg G3215 (B)
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
10 mg G3215 (B)
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
12 mg G3215 (B)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
16 mg G3215 (B)
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
20 mg G3215 (B)
Serious events: 0 serious events
Other events: 3 other events
Deaths: 3 deaths
24 mg G3215 (B)
Serious events: 0 serious events
Other events: 6 other events
Deaths: 6 deaths
Placebo (C)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 4 deaths
0.6 mg/24h (C) Infusion Rate Pump of G3215
Serious events: 0 serious events
Other events: 1 other events
Deaths: 1 deaths
0.7 mg/24h (C) Infusion Rate Pump of G3215
Serious events: 0 serious events
Other events: 2 other events
Deaths: 2 deaths
0.8 mg/24h (C) Infusion Rate Pump of G3215
Serious events: 0 serious events
Other events: 0 other events
Deaths: 1 deaths
1 mg/24h (C) Infusion Rate Pump of G3215
Serious events: 0 serious events
Other events: 1 other events
Deaths: 1 deaths
1.1 mg/24h (C) Infusion Rate Pump of G3215
Serious events: 0 serious events
Other events: 1 other events
Deaths: 1 deaths
1.4 mg/24h (C) Infusion Rate Pump of G3215
Serious events: 0 serious events
Other events: 1 other events
Deaths: 1 deaths
1.5 mg/24h (C) Infusion Rate Pump of G3215
Serious events: 0 serious events
Other events: 2 other events
Deaths: 3 deaths
1.8 mg/24h (C) Infusion Rate Pump of G3215
Serious events: 0 serious events
Other events: 1 other events
Deaths: 1 deaths
2.2 mg/24h (C) Infusion Rate Pump of G3215
Serious events: 0 serious events
Other events: 1 other events
Deaths: 1 deaths
Serious adverse events
| Measure |
Placebo (A) - Saline
n=13 participants at risk
0.9% saline, single dose, subcutaneous injection
Placebo: 0.9% saline
|
0.1 mg Dose G3215 (A1)
n=3 participants at risk
0.1 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
0.5 mg Dose G3215 (A1)
n=3 participants at risk
0.5 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
1.5 mg Dose G3215 (A1)
n=3 participants at risk
1.5 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A2)
n=5 participants at risk
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A3)
n=5 participants at risk
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A4)
n=4 participants at risk
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A5)
n=5 participants at risk
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
8 mg Dose G3215 (A7)
n=5 participants at risk
8 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
10 mg Dose G3215 (A6)
n=5 participants at risk
10 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
12 mg Dose G3215 (A8)
n=5 participants at risk
12 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
16 mg Dose G3215 (A9)
n=4 participants at risk
16 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
32 mg Dose G3215 (A10)
n=5 participants at risk
32 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
48 mg Dose G3215 (A11)
n=5 participants at risk
48 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
Placebo (B) - Saline
n=6 participants at risk
0.9% saline, multiple subcutaneous injections 5 injections over a 4 week treatment period
Placebo: 0.9% saline
|
5 mg G3215 (B)
n=6 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
6 mg G3215 (B)
n=6 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
7 mg G3215 (B)
n=6 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
8 mg G3215 (B)
n=6 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
10 mg G3215 (B)
n=8 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
12 mg G3215 (B)
n=1 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
16 mg G3215 (B)
n=7 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
20 mg G3215 (B)
n=3 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
24 mg G3215 (B)
n=6 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
Placebo (C)
n=4 participants at risk
Placebo: 0.9% saline subcutaneous infusion over a 24 hour treatment period
|
0.6 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 0.6 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
0.7 mg/24h (C) Infusion Rate Pump of G3215
n=2 participants at risk
G3215 subcutaneous infusion of 0.7 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
0.8 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 0.8 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
1 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 1 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
1.1 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 1.1 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
1.4 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 1.4 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
1.5 mg/24h (C) Infusion Rate Pump of G3215
n=3 participants at risk
G3215 subcutaneous infusion of 1.5 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
1.8 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 1.8 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
2.2 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 2.2 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nervous system disorders
Cerebral infarction
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
1/4 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
Other adverse events
| Measure |
Placebo (A) - Saline
n=13 participants at risk
0.9% saline, single dose, subcutaneous injection
Placebo: 0.9% saline
|
0.1 mg Dose G3215 (A1)
n=3 participants at risk
0.1 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
0.5 mg Dose G3215 (A1)
n=3 participants at risk
0.5 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
1.5 mg Dose G3215 (A1)
n=3 participants at risk
1.5 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A2)
n=5 participants at risk
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A3)
n=5 participants at risk
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A4)
n=4 participants at risk
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
4 mg Dose G3215 (A5)
n=5 participants at risk
4 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
8 mg Dose G3215 (A7)
n=5 participants at risk
8 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
10 mg Dose G3215 (A6)
n=5 participants at risk
10 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
12 mg Dose G3215 (A8)
n=5 participants at risk
12 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
16 mg Dose G3215 (A9)
n=4 participants at risk
16 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
32 mg Dose G3215 (A10)
n=5 participants at risk
32 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
48 mg Dose G3215 (A11)
n=5 participants at risk
48 mg G3215 single dose, subcutaneous injection
G3215: Gut hormone analogue
|
Placebo (B) - Saline
n=6 participants at risk
0.9% saline, multiple subcutaneous injections 5 injections over a 4 week treatment period
Placebo: 0.9% saline
|
5 mg G3215 (B)
n=6 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
6 mg G3215 (B)
n=6 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
7 mg G3215 (B)
n=6 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
8 mg G3215 (B)
n=6 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
10 mg G3215 (B)
n=8 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
12 mg G3215 (B)
n=1 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
16 mg G3215 (B)
n=7 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
20 mg G3215 (B)
n=3 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
24 mg G3215 (B)
n=6 participants at risk
G3215 multiple dose, subcutaneous injection:
5 doses over a 4 week treatment period at escalating doses.
G3215: Gut hormone analogue
|
Placebo (C)
n=4 participants at risk
Placebo: 0.9% saline subcutaneous infusion over a 24 hour treatment period
|
0.6 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 0.6 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
0.7 mg/24h (C) Infusion Rate Pump of G3215
n=2 participants at risk
G3215 subcutaneous infusion of 0.7 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
0.8 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 0.8 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
1 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 1 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
1.1 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 1.1 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
1.4 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 1.4 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
1.5 mg/24h (C) Infusion Rate Pump of G3215
n=3 participants at risk
G3215 subcutaneous infusion of 1.5 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
1.8 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 1.8 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
2.2 mg/24h (C) Infusion Rate Pump of G3215
n=1 participants at risk
G3215 subcutaneous infusion of 2.2 mg over a 24 hour treatment period
G3215: Gut hormone analogue
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Retching
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Respiratory, thoracic and mediastinal disorders
Dry throat
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
1/4 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Injection Site Erythema
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
60.0%
3/5 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
80.0%
4/5 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
1/4 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
2/4 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
80.0%
4/5 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
80.0%
4/5 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
4/8 • Number of events 7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
28.6%
2/7 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
66.7%
2/3 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
6/6 • Number of events 13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Injection Site mass
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
3/3 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
80.0%
4/5 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
80.0%
4/5 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
2/4 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
40.0%
2/5 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
60.0%
3/5 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
5/5 • Number of events 5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
4/4 • Number of events 5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
80.0%
4/5 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
5/5 • Number of events 5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
66.7%
4/6 • Number of events 14 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
3/6 • Number of events 7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
4/8 • Number of events 9 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
42.9%
3/7 • Number of events 5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
66.7%
2/3 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
66.7%
4/6 • Number of events 17 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Injection site pain
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
40.0%
2/5 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
1/4 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
60.0%
3/5 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
60.0%
3/5 • Number of events 5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
14.3%
1/7 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Injection site reaction
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
40.0%
2/5 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Infections and infestations
Rash pustular
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Injection site bruising
|
7.7%
1/13 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
60.0%
3/5 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Injection site pruritus
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
40.0%
2/5 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
1/4 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Chest pain
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Chills
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Asthenia
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Catheter site pain
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Feeling cold
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Feeling hot
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
1/4 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Injection site rash
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Injection site swelling
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Thirst
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Vessel puncture site bruise
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Nausea
|
7.7%
1/13 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
80.0%
4/5 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
60.0%
3/5 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
5/5 • Number of events 10 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
3/6 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
6/6 • Number of events 15 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
3/6 • Number of events 6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
83.3%
5/6 • Number of events 5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
2/8 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
14.3%
1/7 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
66.7%
2/3 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
3/6 • Number of events 11 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
2/2 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
66.7%
2/3 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
40.0%
2/5 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
40.0%
2/5 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
80.0%
4/5 • Number of events 5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
66.7%
4/6 • Number of events 6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
3/6 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
3/6 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
62.5%
5/8 • Number of events 9 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
66.7%
4/6 • Number of events 9 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
1/2 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
66.7%
2/3 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
40.0%
2/5 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
60.0%
3/5 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Abdominal discomfort
|
7.7%
1/13 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
40.0%
2/5 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Eructation
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Haematemesis
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Toothache
|
7.7%
1/13 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Nervous system disorders
Headache
|
15.4%
2/13 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
40.0%
2/5 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Nervous system disorders
Dizziness
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
2/8 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
3/6 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Nervous system disorders
Cerebral infarction
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
1/4 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Metabolism and nutrition disorders
Decreased appetite
|
7.7%
1/13 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
80.0%
4/5 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
40.0%
2/5 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
5/5 • Number of events 5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
83.3%
5/6 • Number of events 5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
83.3%
5/6 • Number of events 6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
3/6 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
66.7%
4/6 • Number of events 5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
37.5%
3/8 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
3/6 • Number of events 5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Metabolism and nutrition disorders
Food craving
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Investigations
Lipase increased
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
40.0%
2/5 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
2/4 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Investigations
Amylase increased
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
1/4 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
1/4 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
1/4 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
40.0%
2/5 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
3/6 • Number of events 4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
14.3%
1/7 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
7.7%
1/13 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
1/4 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
1/4 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Musculoskeletal and connective tissue disorders
Pain in jaw
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Injury, poisoning and procedural complications
Arthropod sting
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
25.0%
1/4 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Injury, poisoning and procedural complications
Forearm fracture
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Skin and subcutaneous tissue disorders
Petechiae
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Skin and subcutaneous tissue disorders
Skin burning sensation
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
20.0%
1/5 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Early satiety
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
14.3%
1/7 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Injection site oedema
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Application site erythema
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Fatigue
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Injection site induration
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Instillation site warmth
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Malaise
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
2/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
14.3%
1/7 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
50.0%
1/2 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Change of bowel habit
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Gastrointestinal disorders
Faeces discoloured
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Nervous system disorders
Lethargy
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Nervous system disorders
Somnolence
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Nervous system disorders
Tremor
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Injury, poisoning and procedural complications
Contusion
|
7.7%
1/13 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Injury, poisoning and procedural complications
Joint injury
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Injury, poisoning and procedural complications
Tongue injury
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Injury, poisoning and procedural complications
Tooth fracture
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Injury, poisoning and procedural complications
Wound
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Infections and infestations
Localised infection
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Eye disorders
Vision blurred
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Eye disorders
Eye pain
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Eye disorders
Ocular hyperaemia
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
12.5%
1/8 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Respiratory, thoracic and mediastinal disorders
Increased upper airway secretion
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
14.3%
1/7 • Number of events 2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Skin and subcutaneous tissue disorders
Onychoclasis
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Cardiac disorders
Palpitations
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Reproductive system and breast disorders
Erectile dysfunction
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
16.7%
1/6 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
General disorders
Injection site irritation
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
100.0%
1/1 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
|
Skin and subcutaneous tissue disorders
Pruritus generalised
|
0.00%
0/13 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/5 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/8 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/7 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/3 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/6 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/4 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/2 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
33.3%
1/3 • Number of events 1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
0.00%
0/1 • Up to 21 weeks from participant start date
The safety evaluation will include blood pressure, pulse rate, ECG parameters, clinical laboratory tests (haematology, serum biochemistry, coagulation, urinalysis and urine microscopy).
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place